Aragen Life Sciences
Aragen Life Sciences, a prominent player in the biotechnology sector, is headquartered in India and operates extensively across major regions, including North America and Europe. Founded in 2000, the company has established itself as a leader in providing integrated solutions for drug discovery, development, and manufacturing. Aragen's core offerings encompass a wide range of services, including biologics, small molecules, and custom research, distinguished by their commitment to innovation and quality. The company has achieved significant milestones, such as expanding its capabilities in biologics and securing partnerships with leading pharmaceutical firms. With a strong market position, Aragen Life Sciences is recognised for its expertise and reliability, making it a preferred partner for clients seeking comprehensive life science solutions.
DitchCarbon Score
How does Aragen Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aragen Life Sciences's score of 83 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aragen Life Sciences's reported carbon emissions
In 2023, Aragen Life Sciences reported total greenhouse gas emissions of approximately 49,720,000 kg CO2e, comprising 9,544,000 kg CO2e from Scope 1, 37,600,000 kg CO2e from Scope 2, and 5,550,720 kg CO2e from Scope 3 emissions. This marked a significant reduction in Scope 1 emissions compared to 2022, where they were approximately 13,252,000 kg CO2e, and a slight increase in Scope 2 emissions from 28,770,000 kg CO2e. Aragen Life Sciences has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by FY2050. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 50.4% and Scope 3 emissions by the same percentage by FY2033, using FY2023 as the baseline year. Long-term goals include a 90% reduction in absolute emissions across all scopes by FY2050. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to limiting global warming to 1.5°C. The commitment includes land-related emissions and removals from bioenergy feedstocks, reflecting a comprehensive approach to sustainability in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 10,268,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 25,554,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aragen Life Sciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
